Experienced executive, scientist, investor, and board director with demonstrated leadership history in the biotechnology/pharmaceuticals, diagnostics, device, and healthcare services sectors. R&D and finance professional skilled in company building, Product Management, Board Management, negotiation, compensation/HR, and audit/compliance. Ability to drive actionable innovation in complex business environments. Experience in multiple therapeutic areas including oncology, CNS, cardiovascular, and infectious disease, with strong digital health experience.
Paul Klingenstein founded Aberdare in 1999. His recent focus has been on technologies which drive transformational efficiencies in care, leading Aberdare commitments in areas such as personalized medicine (Clovis Oncology) and biosensor systems and data analytics (mc10, RxAnte). Earlier at Aberdare, he helped establish the firm as a leading healthcare venture investor through commitments to more traditional technologies such as drug discovery and development and highly engineered interventional devices. Prior to founding Aberdare, Paul was an advisor to the Rockefeller Foundation, where he helped launch an early public private partnership (IAVI), directed at finding a broadly effective vaccine for HIV. Earlier in his career he worked at Accel Partners and Warburg Pincus. Paul received his AB in anthropology from Harvard and his MBA from Stanford.
Vijay Lathi is a Managing Director focused on information convergence and diagnostics investments. Vijay joined Sprout in 1998, was promoted to Partner in 2003, and was one of the founders of New Leaf in 2005. Prior to focusing on information convergence, Vijay’s investment activity covered a range of healthcare technologies including HCIT, diagnostics and therapeutic platforms, and was the founding investor in both Ilypsa (sold to Amgen) and Relypsa (RLYP). Prior to joining Sprout, Vijay was an analyst in the Healthcare Venture Capital Group at Robertson Stephens & Co. and analyst at Cornerstone Research, a consulting firm focused on financial and economic analysis for business litigation. Vijay graduated from the Massachusetts Institute of Technology and Stanford University where he received his B.S. and M.S. in Chemical Engineering, with an emphasis on the application of engineering to life science technology
William Gerber, MD, is an Investment Partner at Bay City Capital and has been with the firm since September 1999. He was most recently President and Chief Executive Officer of Epoch BioSciences, which was acquired by Nanogen in 2004. Prior to joining Epoch, Dr. Gerber served as President and Chief Executive Officer of diaDexus LLC, a joint venture established by Incyte Pharmaceuticals and SmithKline Beecham to apply genomics to the discovery of novel diagnostic products. Dr. Gerber previously served as Vice President and Chief Operating Officer of Onyx Pharmaceuticals, as President of Chiron Diagnostics, and as Senior Vice President and General Manager of the PCR Division of Cetus Corporation. Dr. Gerber is a member of the board of directors of Aviir, Inc., Conatus Pharmaceuticals, Sangamo Biosciences and Vivaldi Biosciences. He also served on and was President of the Board of Medical Quality Assurance, State of California. He received his MD and BS degrees from University of California, San Francisco Medical Center after attending Dartmouth College.